公开(公告)号：EP2638163A1

公开(公告)日：2013-09-18

申请号：EP11840099.3

申请日：2011-11-12

Applicant: The General Hospital Corporation

Inventor： LEE, Jeannie T. ,  ZHAO, Jing ,  SARMA, Kavitha ,  BOROWSKY, Mark ,  OHSUMI, Toshiro Kendrick

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs. d

Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如多梳抑制复合物2，抑制性核酸以及用于靶向lncRNA的方法和组合物。

公开(公告)号：EP1599586B9

公开(公告)日：2012-03-14

申请号：EP04715568.4

申请日：2004-02-27

Applicant: Oncotherapy Science, Inc.

Inventor： NAKAMURA, Yusuke ,  FURUKAWA, Yoichi

IPC: C12N15/11

CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y201/01043

Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a ZNFN3A1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumer cell, for example liver or colon cancer cell, particularly HCC or colorectal adenocarcinoma.

公开(公告)号：EP2311948A1

公开(公告)日：2011-04-20

申请号：EP10180084.5

申请日：2004-02-27

Applicant: Onco Therapy Science, Inc.

Inventor： Nakamura, Yusuke ,  Furukawa, Yoichi

IPC: C12N15/11 ,  C12N15/12 ,  A61K48/00 ,  C12N15/113

CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y201/01043

Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a ZNFN3A1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumer cell, for example liver or colon cancer cell, particularly HCC or colorectal adenocarcinoma.

Abstract translation: 本发明的特征在于通过使细胞与ZNFN3A1 siRNA的组合物接触来抑制癌细胞生长的方法。 治疗癌症的方法也在本发明的范围内。 本发明还特征在于包括核酸序列和载体的产物以及包含它们的组合物，可用于所提供的方法。 本发明还提供抑制肿瘤细胞的方法，例如肝脏或结肠癌细胞，特别是HCC或结肠直肠腺癌。

公开(公告)号：EP1765994B1

公开(公告)日：2009-11-18

申请号：EP05804853.9

申请日：2005-05-27

Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Inventor： ZHANG, Yi ,  CAO, Ru

IPC: C12N9/10 ,  C12N5/10

CPC classification number: C12N9/1007 ,  C07K14/82 ,  C07K2319/20 ,  C12N2799/026 ,  C12Y201/01043 ,  G01N2333/91011

公开(公告)号：US20240255509A1

公开(公告)日：2024-08-01

申请号：US18506086

申请日：2023-11-09

Applicant: Aelan Cell Technologies, Inc.

Inventor： Victoria LUNYAK ,  James Robert TOLLERVEY

IPC: G01N33/573 ,  C07K14/47 ,  C07K16/18 ,  C12N9/10 ,  C12P21/02 ,  C12P21/06 ,  G01N33/543 ,  G01N33/68

CPC classification number: G01N33/573 ,  C07K14/47 ,  C07K16/18 ,  C12N9/1007 ,  C12P21/02 ,  C12P21/06 ,  C12Y201/01043 ,  G01N33/54306 ,  G01N33/6896 ,  C12Y201/01 ,  G01N2800/2821 ,  G01N2800/50

Abstract: Provided herein are H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides and methods of use for diagnostics and therapeutics. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may be used in the treatment of methylated H1.0-related diseases or conditions in an individual. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may also be used for the detection and quantification of a histone H1.0 protein or fragment thereof, comprising a dimethylated lysine at lysine residue 180 (H1.0K180me2); such compositions and methods are useful for detecting replicative senescence, DNA damage, genotoxic stress, radiation exposure, Alzheimer's disease, are useful for monitoring therapeutic regimens, patient stratification, drug screening, and may serve as a marker of biological aging in a system.

公开(公告)号：US11819554B2

公开(公告)日：2023-11-21

申请号：US15760765

申请日：2016-09-16

Applicant: University of Massachusetts

Inventor： Michael R. Green ,  Minggang Fang ,  Walter Kowtoniuk

IPC: A61K31/711 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/395 ,  A61K48/00 ,  A61K31/5377 ,  A61K31/549 ,  A61K31/706 ,  A61K31/713 ,  C12Q1/6883 ,  C12N15/113 ,  A61K31/7088 ,  A61K31/404 ,  A61K31/546 ,  A61K31/167 ,  A61K31/497 ,  A61K31/506 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/522 ,  A61K31/496 ,  A61P25/14 ,  A61P15/02 ,  A61K31/7105

CPC classification number: A61K48/005 ,  A61K31/167 ,  A61K31/404 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/546 ,  A61K31/549 ,  A61K31/706 ,  A61K31/7088 ,  A61K31/711 ,  A61K31/713 ,  A61K31/7105 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/3955 ,  A61K48/0016 ,  A61P15/02 ,  A61P25/14 ,  C12N15/113 ,  C12Q1/6883 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y603/02019

Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

公开(公告)号：US20190233805A1

公开(公告)日：2019-08-01

申请号：US16151895

申请日：2018-10-04

Applicant: The Regents of the University of California

Inventor： David J Segal ,  Henriette O'Geen ,  Joel P. Mackay ,  Peggy J. Farnham

IPC: C12N9/22 ,  C12N9/10 ,  C07K14/47

CPC classification number: C12N9/22 ,  C07K14/4702 ,  C07K2319/09 ,  C07K2319/43 ,  C07K2319/81 ,  C12N9/1007 ,  C12Y201/01037 ,  C12Y201/01043

Abstract: Provided herein are fusion proteins comprising a catalytically inactive Cas9 domain and an effector domain. The fusion proteins of the present invention can be used to, for example, produce epigenetic modifications at target chromatin sites. Nucleic acids and expression vectors encoding the fusion proteins, as well as cells comprising the fusion proteins, are also provided herein.

公开(公告)号：US20190192533A1

公开(公告)日：2019-06-27

申请号：US16195777

申请日：2018-11-19

Applicant: Duke University

Inventor： Victor J. Dzau ,  Maria Mirotsou

IPC: A61K31/551 ,  A61P9/00 ,  C07D487/04 ,  C07D401/14 ,  A61K45/06 ,  A61K31/437 ,  A61P9/12 ,  A61K35/34 ,  A61P9/10 ,  C12N15/113

CPC classification number: A61K31/551 ,  A61K31/437 ,  A61K35/34 ,  A61K45/06 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  C07D401/14 ,  C07D487/04 ,  C12N15/1137 ,  C12N2310/141 ,  C12N2320/30 ,  C12Y201/01043 ,  C12Y201/01125 ,  C12Y207/10002 ,  C12Y207/11001

Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.

公开(公告)号：US20180363008A1

公开(公告)日：2018-12-20

申请号：US16017157

申请日：2018-06-25

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Yi Zhang ,  Shogo Matoba

IPC: C12N15/877 ,  A01K67/027 ,  C12N15/113 ,  C12N5/0735 ,  C12N5/073

CPC classification number: C12N15/877 ,  A01K67/0273 ,  A01K2227/105 ,  C12N5/0604 ,  C12N5/0606 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2517/04 ,  C12Y201/01043

Abstract: The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT) and the consequent production of nuclear transfer ESC (ntESC) and transgenic cells and/or non-human animals. More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of donor somatic cells prevents efficient somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of SCNT by exogenous or overexpression of the demethylase Kdm4 family and/or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases Suv39h1 and/or Suv39h2.

公开(公告)号：US09889180B2

公开(公告)日：2018-02-13

申请号：US14443602

申请日：2013-11-19

Applicant: Agency for Science, Technology and Research

Inventor： Qiang Yu ,  Zhen Ning Wee

IPC: A61K31/713 ,  A61K31/706 ,  A61K31/437 ,  A61K38/21 ,  G01N33/574 ,  C07K16/40 ,  C07K14/57 ,  C12Q1/68 ,  C12N15/113

CPC classification number: A61K38/217 ,  A61K31/437 ,  A61K31/706 ,  A61K31/713 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Y201/01043 ,  G01N33/57492 ,  G01N33/57496 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.